Table 1 Characteristics of patients with schizophrenia at admission.

Females / males

15/20

Age [years], median (interquartile range)

30 (23–40)

Amount of psychotic episodes [n], median (interquartile range)

2 (2–9)

First psychotic episode, n (%)

12/35 (34%)

Second psychotic episode, n (%)

9/35 (26%)

3 or more psychotic episodes, n (%)

14/35 (40%)

Time between symptom onset and LP [months], median (interquartile range)

38 (7-118)

Substance users

Smoker (at least 12 months), n (%)

25/35 (71%)

Alcohol use disorder diagnosis, n (%)

8/35 (23%)

Cannabis (at least 12 months), n (%)

8/35 (23%)

Other drugs, n (%)

5/35 (14%)

Clinial presentation of schizophrenia

Delusions / without delusions [n]

20/15

Hallucination / without hallucinations [n]

19/16

Assured disturbance of self-experience / without assured disturbance of self-experience [n]*

10/25

Disorganization / without disorganization [n]

31/4

Psychomotor drive reduced / psychomotor drive increased [n]

24/11

Suicidal ideation / without suicidal ideation [n]

6/29

Amount of suicide attempts [n], median (min-max)

0 (0–5)

Treatment

Antipsychotic pharmaco-therapy, n (%)

28/35 (80%)

First anti-psychotic pharmaco-therapy attempt, n (%)

13/28 (46%)

Second anti-psychotic pharmaco-therapy attempt, n (%)

3/28 (11%)

3 or more anti-psychotic pharmaco-therapy attempts, n (%)

12/28 (43%)

Without antipsychotic pharmaco-therapy, n (%)

7/35 (20%)

Antipsychotics at sampling, n (%)

28/35 (80%)

Typical antipsychotic with high potency, n (%)

15/35 (43%)

Typical antipsychotic with low potency, n (%)

5/35 (14%)

Atypical antipsychotics, n (%)

18/35 (51%)

Clozapine, n (%)

2/18 (11%)

Olanzapine, n (%)

6/18 (33%)

Antidepressants at sampling, n (%)

4/35 (11%)

SSRI, n (%)

1/35 (3%)

SSNRI, n (%)

1/35 (3%)

Mirtazapine, n (%)

2/35 (6%)

Tricyclics, n (%), Lithium, n (%)

0/35, 0/35

Benzodiazepines, n (%)

18/35 (51%)

Anticonvulsants, n (%)

3/35 (9%)